Interestingly, newer T2D therapies such as GLP1-receptor agonists (liraglutide, semaglutide), novel dual and triple peptides (e.g. tirzepatide) and SGLT2-inhibitors have been shown to decrease levels of ALT and lower liver fat (measured by MRI-PDFF) in people with T2D and areas of fibrosis, ALT/AST and hepatic lipid content in murine NASH models (27, 28). The gene discussed is GPT; the disease is type 2 diabetes mellitus.